Wechselwirkungen von Heparin

Aminocaproic acid must not be used in the presence of DIC without concomitant heparin. (Fachinformation zu Aminocapronsäure, Gegenanzeigen)

Warfarin Potentiates anticoagulant response and can result in serious or fatal bleeding. (Fachinformation zu Amiodaron, Arzneimittelwechselwirkungen)

Avoid use of heparin after use of andexanet alfa for the reversal of direct Factor Xa inhibitors (apixaban and rivaroxaban). (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Anticoagulants: warfarin ↑ warfarin Coadministration with REYATAZ has the potential to produce serious and/or life-threatening bleeding and has not been studied. (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

Among patients who experienced an AST, one fatality (0.03%) occurred in a bivalirudin treated patient and one fatality (0.03%) in a heparin treated patient. (Fachinformation zu Bivalirudin, Warnhinweise und Vorsichtsmaßnahmen)

To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.6 , 2.7 , 2.8 , 5.1 ). (Fachinformation zu Dabigatran, Boxed Warning (umrahmter Warnhinweis))

In these patients another anticoagulant should be used ( 5.1 ). (Fachinformation zu Edoxaban, Boxed Warning (umrahmter Warnhinweis))

…Voxilaprevir ↓ velpatasvir ↓ voxilaprevir Coadministration of efavirenz and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir Other agents Anticoagulant:Warfarin ↑ or ↓ warfarin Monitor international normalised ratio (INR) and adjust warfarin dosage if necessary. (Fachinformation zu Efavirenz, Arzneimittelwechselwirkungen)

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. (Fachinformation zu Enoxaparin, Boxed Warning (umrahmter Warnhinweis))

Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (Fachinformation zu Epoprostenol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. (Fachinformation zu Fondaparinux, Boxed Warning (umrahmter Warnhinweis))

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (Fachinformation zu Prasugrel, Boxed Warning (umrahmter Warnhinweis))

Protamine sulfate should not be given when bleeding occurs without prior heparin use. (Fachinformation zu Protamin, Boxed Warning (umrahmter Warnhinweis))

…Antipsychotics Haloperidol Decrease plasma concentrations by 70% Lurasidone Prevention or Management: Concomitant use is contraindicated (See CONTRAINDICATIONS ) Decrease exposure Oral Anticoagulants Prevention or Management: Perform prothrombin time daily or as frequently as necessary to establish and maintain the required dose of anticoagulant Warfarin Decrease… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

Anticoagulant: rivaroxaban ↑ rivaroxaban Avoid concomitant use of rivaroxaban and ritonavir. (Fachinformation zu Ritonavir, Arzneimittelwechselwirkungen)

Avoid use of heparin after use of andexanet alfa for the reversal of direct Factor Xa inhibitors (apixaban and rivaroxaban). (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (Fachinformation zu Tamoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Heparin-induced thrombocytopenia (HIT): Initial therapy with warfarin sodium in HIT has resulted in cases of amputation and death. (Fachinformation zu Warfarin, Warnhinweise und Vorsichtsmaßnahmen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Dicumarol Clinical Impact Allopurinol tablets prolongs the half-life of the anticoagulant, dicumarol. (Fachinformation zu Allopurinol, Arzneimittelwechselwirkungen)

• Injection site bleeding may occur in patients taking anticoagulants, such as warfarin or heparin. (Fachinformation zu Alprostadil, Warnhinweise und Vorsichtsmaßnahmen)

Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Fachinformation zu Alteplase, Warnhinweise und Vorsichtsmaßnahmen)

…other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine. (Fachinformation zu Amlodipin und Valsartan, Arzneimittelwechselwirkungen)

Concomitant use of amoxicillin and oral anticoagulants may increase the prolongation of prothrombin time. (Fachinformation zu Amoxicillin, Arzneimittelwechselwirkungen)

Concomitant use Amoxicillin and Clavulanate Potassium Extended Release Tablets and oral anticoagulants may increase the prolongation of prothrombin time. (Fachinformation zu Amoxicillin und Clavulansäure, Arzneimittelwechselwirkungen)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Fachinformation zu Anagrelid, Warnhinweise und Vorsichtsmaßnahmen)

Heparin: Allow sufficient time for heparin’s effect on activated partial thromboplastin time (aPTT) to decrease before initiating Argatroban Injection therapy. (Fachinformation zu Argatroban, Arzneimittelwechselwirkungen)

• Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. (Fachinformation zu Atovaquon und Proguanil, Arzneimittelwechselwirkungen)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (Fachinformation zu Azithromycin, Arzneimittelwechselwirkungen)

Concomitant administration of betaxolol with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin. (Fachinformation zu Betaxolol, Arzneimittelwechselwirkungen)

Closely monitor the Prothrombin Time (PT) and International Normalized Ratio (INR), and adjust the anticoagulant dose as needed. (Fachinformation zu Bicalutamid, Warnhinweise und Vorsichtsmaßnahmen)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Fachinformation zu Bismutsubcitrat, Metronidazol und Tetracyclin, Warnhinweise und Vorsichtsmaßnahmen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (Fachinformation zu Capecitabin, Arzneimittelwechselwirkungen)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (Fachinformation zu Carbamazepin, Arzneimittelwechselwirkungen)

Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antibacterial therapy, and patients receiving anticoagulant therapy. (Fachinformation zu Cefalexin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefixim, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Celecoxib, Warnhinweise und Vorsichtsmaßnahmen)

By a mechanism that is not understood, quinidine potentiates the anticoagulatory action of warfarin , and the anticoagulant dosage may need to be reduced. (Fachinformation zu Chinidin, Arzneimittelwechselwirkungen)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

Though resolution has occurred after reduction or discontinuation of cyclosporine and 1) administration of streptokinase and heparin or 2) plasmapheresis, this appears to depend upon early detection with Indium 111 labeled platelet scans (see ADVERSE REACTIONS) . (Fachinformation zu Ciclosporin, Warnhinweise)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Drug Interactions Cimetidine tablets, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination… (Fachinformation zu Cimetidin, Arzneimittelwechselwirkungen)

Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk. (Fachinformation zu Citalopram, Warnhinweise und Vorsichtsmaßnahmen)

Oral Anticoagulants: There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. (Fachinformation zu Clarithromycin, Warnhinweise und Vorsichtsmaßnahmen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Monitor anticoagulant activity closely in patients receiving warfarin or other coumarins. (Fachinformation zu Cyclophosphamid, Arzneimittelwechselwirkungen)

Anticoagulants : Direct Oral Anticoagulants (DOACs) apixaban ↑ apixaban Due to potentially increased bleeding risk, dosing recommendations for co-administration of apixaban with PREZISTA/ritonavir depend on the apixaban dose. (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban ↑ apixaban Due to potentially increased bleeding risk, dosing recommendations for co-administration of apixaban with PREZCOBIX or PREZCOBIX PED depend on the apixaban dose. (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Fachinformation zu Deferasirox, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Fachinformation zu Demeclocyclin, Arzneimittelwechselwirkungen)

• Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.4 ). (Fachinformation zu Desvenlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

(‎ 5.3 ) • Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism. (Fachinformation zu Dexamethason, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac und Misoprostol, Warnhinweise und Vorsichtsmaßnahmen)

Dicloxacillin may reduce the anticoagulant response to dicumarol and warfarin. (Fachinformation zu Dicloxacillin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Diflunisal, Warnhinweise)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Fachinformation zu Disulfiram, Arzneimittelwechselwirkungen)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Fachinformation zu Dofetilid, Arzneimittelwechselwirkungen)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Fachinformation zu Doxycyclin, Arzneimittelwechselwirkungen)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of antiplatelet drugs and anticoagulants may increase this risk. (Fachinformation zu Duloxetin, Warnhinweise und Vorsichtsmaßnahmen)

- 7.1 Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. (Fachinformation zu Econazol, Arzneimittelwechselwirkungen)

Concomitant Drug Class: Drug Name Effect Clinical Comment Anticoagulant: Warfarin ↑ or ↓ warfarin Monitor INR and adjust warfarin dosage if necessary. (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Arzneimittelwechselwirkungen)

Anticoagulants: Direct Oral Anticoagulants (DOACs) apixaban rivaroxaban betrixaban dabigatran edoxaban ↑ apixaban Due to potentially increased bleeding risk, dosing recommendations for coadministration with GENVOYA depends on the apixaban dose. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

• Hemorrhage in patients taking warfarin: Regularly monitor INR in patients taking warfarin or other coumarin-derivative anticoagulants. (Fachinformation zu Erlotinib, Warnhinweise und Vorsichtsmaßnahmen)

There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. (Fachinformation zu Erythromycin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (Fachinformation zu Escitalopram, Warnhinweise und Vorsichtsmaßnahmen)

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs. (Fachinformation zu Etacrynsäure, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Etodolac, Warnhinweise)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

Coumarin Anticoagulants: Obtain INR before VYTORIN initiation and monitor INR during VYTORIN dosage initiation or adjustment. (Fachinformation zu Ezetimib und Simvastatin, Arzneimittelwechselwirkungen)

Increased Bleeding Risk with Coumarin Anticoagulants Exercise caution when co-administering anticoagulants with fenofibrate capsules because of the potentiation of coumarin-type anticoagulant effects in prolonging the prothrombin time/International Normalized Ratio (PT/INR). (Fachinformation zu Fenofibrat, Warnhinweise und Vorsichtsmaßnahmen)

Increased Bleeding Risk with Coumarin Anticoagulants Exercise caution when co-administering anticoagulants with fenofibric acid delayed-release capsules because of the potentiation of coumarin-type anticoagulant effects in prolonging the prothrombin time/International Normalized Ratio (PT/INR). (Fachinformation zu Fenofibrinsäure, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Fenoprofen, Warnhinweise und Vorsichtsmaßnahmen)

Coumarin-type anticoagulants Prothrombin time may be increased in patients receiving concomitant fluconazole and coumarin-type anticoagulants. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

Oral anticoagulants — decreased prothrombin time response. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

Closely monitor patients receiving concomitant coumarin-derivative anticoagulants such as warfarin for INR or prothrombin time in order to adjust the anticoagulant dose accordingly [see Drug Interactions (7) ]. (Fachinformation zu Fluorouracil, Warnhinweise und Vorsichtsmaßnahmen)

Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin. (Fachinformation zu Fluoxetin, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Flurbiprofen, Warnhinweise und Vorsichtsmaßnahmen)

Therefore close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when Eulexin ® capsules are administered concomitantly with warfarin. (Fachinformation zu Flutamid, Arzneimittelwechselwirkungen)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (Fachinformation zu Fluvoxamin, Warnhinweise und Vorsichtsmaßnahmen)

…Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable. (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (Fachinformation zu Fulvestrant, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant Anticoagulants – Caution should be exercised when warfarin is given in conjunction with LOPID. (Fachinformation zu Gemfibrozil, Warnhinweise)

Ginkgo kann das Blutungsrisiko erhöhen, wenn es zusammen mit Antikoagulanzien oder Thrombozytenaggregationshemmern eingenommen wird. (NCCIH, Ginkgo)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. (Fachinformation zu Griseofulvin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Intervention: Monitor coagulation indices in patients receiving ALKINDI SPRINKLE and concomitant warfarin to maintain the desired anticoagulant effect. (Fachinformation zu Hydrocortison, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (Fachinformation zu Icosapent-Ethyl, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

Patients receiving Ketoprofen Capsules, USP who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. (Fachinformation zu Ketoprofen, Warnhinweise und Vorsichtsmaßnahmen)

The concurrent use of ketorolac tromethamine and therapy that affects hemostasis, including prophylactic low-dose heparin (2500 to 5000 units q12h), warfarin and dextrans have not been studied extensively, but may also be associated with an increased risk of bleeding. (Fachinformation zu Ketorolac, Warnhinweise und Vorsichtsmaßnahmen)

A significantly increased risk of DVT (7.4%) and of PE (3.7%) occurred in patients with MM after at least one prior therapy who were treated with REVLIMID and dexamethasone therapy compared to patients treated in the placebo and dexamethasone group (3.1% and 0.9%) in clinical trials with varying use of anticoagulant therapies. (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

…Skyla with caution after careful assessment if any of the following conditions exist, and consider removal of the system if any of them arise during use: • Coagulopathy or use of anticoagulants • Migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia • Exceptionally severe headache • Marked increase of… (Fachinformation zu Levonorgestrel, Warnhinweise und Vorsichtsmaßnahmen)

Oral Anticoagulants Levothyroxine increases the response to oral anticoagulant therapy. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Oral Anticoagulants Liothyronine sodium increases the response to oral anticoagulant therapy. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin. (Fachinformation zu Lovastatin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Mefenaminsäure, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Meloxicam, Warnhinweise und Vorsichtsmaßnahmen)

Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (Fachinformation zu Methylprednisolon, Arzneimittelwechselwirkungen)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Methyltestosteron, Arzneimittelwechselwirkungen)

Anticoagulants Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; dosage adjustments may be necessary. (Fachinformation zu Metolazon, Arzneimittelwechselwirkungen)

Warfarin and Other Oral Anticoagulants : LIKMEZ can potentiate the anticoagulant effect. (Fachinformation zu Metronidazol, Arzneimittelwechselwirkungen)

Warfarin: Miconazole may enhance anticoagulant effect. (Fachinformation zu Miconazol, Arzneimittelwechselwirkungen)

Mifepristone should be used with caution in women who have hemorrhagic disorders or are receiving concurrent anticoagulant therapy. (Fachinformation zu Mifepriston, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Milnacipran, Warnhinweise und Vorsichtsmaßnahmen)

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Fachinformation zu Minocyclin, Arzneimittelwechselwirkungen)

Interacting Drug Interaction Warfarin Anticoagulant effect of warfarin may be enhanced. (Fachinformation zu Moxifloxacin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Nabumeton, Warnhinweise)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen und Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

Caution should be observed when niacin extended-release tablets are administered concomitantly with anticoagulants; platelet counts should be monitored closely in such patients. (Fachinformation zu Nicotinsäure (Niacin), Warnhinweise und Vorsichtsmaßnahmen)

Antithrombotics Coumarins: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered. (Fachinformation zu Nifedipin, Arzneimittelwechselwirkungen)

Anticoagulants Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. (Fachinformation zu Nintedanib, Arzneimittelwechselwirkungen)

Anticoagulants warfarin ↑↓ warfarin Closely monitor international normalized ratio (INR) if co-administration with warfarin is necessary. rivaroxaban ↑ rivaroxaban Increased bleeding risk with rivaroxaban. (Fachinformation zu Nirmatrelvir und Ritonavir, Arzneimittelwechselwirkungen)

Warfarin Some quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. (Fachinformation zu Ofloxacin, Arzneimittelwechselwirkungen)

Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin [see Warnings and Precautions ( 5.16 )] . (Fachinformation zu Olanzapin und Fluoxetin, Arzneimittelwechselwirkungen)

…Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium. (Fachinformation zu Olmesartan, Arzneimittelwechselwirkungen)

Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. (Fachinformation zu Omega-3-Säurenethylester, Arzneimittelwechselwirkungen)

Anticoagulants including Warfarin Vitamin K absorption may be decreased with ORLISTAT. (Fachinformation zu Orlistat, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Hemorrhage : Increase frequency of monitoring in patients who are receiving oxaliplatin injection with fluorouracil/leucovorin and oral anticoagulants (5.9) (Fachinformation zu Oxaliplatin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Oxaprozin, Warnhinweise und Vorsichtsmaßnahmen)

Chronic oral acetaminophen use at a dose of 4,000 mg/day has been shown to cause an increase in international normalized ratio (INR) in some patients who have been stabilized on sodium warfarin as an anticoagulant. (Fachinformation zu Paracetamol, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (Fachinformation zu Paroxetin, Warnhinweise und Vorsichtsmaßnahmen)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. (Fachinformation zu Perindopril, Arzneimittelwechselwirkungen)

Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. (Fachinformation zu Phenobarbital, Hyoscyamin, Atropin und Scopolamin, Warnhinweise)

…Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable. (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

Anticoagulants Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. (Fachinformation zu Phytomenadion (Vitamin K1), Arzneimittelwechselwirkungen)

Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (Fachinformation zu Piperacillin und Tazobactam, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Fachinformation zu Pomalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (Fachinformation zu Prednisolon, Arzneimittelwechselwirkungen)

Anticoagulant agents: May enhance or diminish anticoagulant effects. (Fachinformation zu Prednison, Arzneimittelwechselwirkungen)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (Fachinformation zu Propylthiouracil, Arzneimittelwechselwirkungen)

The anticoagulant effect of a single dose of warfarin (measured by prothrombin time) was not significantly changed by quinapril coadministration twice-daily. (Fachinformation zu Quinapril, Arzneimittelwechselwirkungen)

…Within Class Antiarrhythmics Disopyramide, mexiletine, quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Salsalat, Warnhinweise)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (Fachinformation zu Sertralin, Warnhinweise und Vorsichtsmaßnahmen)

In addition, the combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. (Fachinformation zu Sildenafil, Warnhinweise und Vorsichtsmaßnahmen)

Coumarin Anticoagulants: Obtain INR before ZOCOR initiation and monitor INR during ZOCOR dosage initiation or adjustment. (Fachinformation zu Simvastatin, Arzneimittelwechselwirkungen)

Anticoagulants: dabigatran etexilate ↑ dabigatran Clinical monitoring of dabigatran is recommended when coadministered with VOSEVI. (Fachinformation zu Sofosbuvir und Velpatasvir, Arzneimittelwechselwirkungen)

Examples of drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium… (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

…potassium-sparing diuretics • ACE inhibitors • angiotensin II receptor antagonists • aldosterone blockers • non-steroidal anti-inflammatory drugs (NSAIDs), e.g., indomethacin • heparin and low molecular weight heparin • other drugs or conditions known to cause hyperkalemia • potassium supplements • diet rich in potassium • salt substitutes containing potassium Spironolactone… (Fachinformation zu Spironolacton und Hydrochlorothiazid, Warnhinweise)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (Fachinformation zu Sugammadex, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Administration of a sulfonamide may increase the effect of oral anticoagulants and methotrexate, probably by displacement of these drugs from binding sites on plasma albumin. (Fachinformation zu Sulfadiazin, Arzneimittelwechselwirkungen)

It has been reported that sulfamethoxazole and trimethoprim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Sulindac, Warnhinweise)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (Fachinformation zu Tenecteplase, Warnhinweise und Vorsichtsmaßnahmen)

Frequent monitoring of INR and prothrombin time may be necessary in patients taking anticoagulants, especially at the initiation and termination of androgen therapy. (Fachinformation zu Testosteron, Arzneimittelwechselwirkungen)

Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (Fachinformation zu Tetracyclin, Arzneimittelwechselwirkungen)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (Fachinformation zu Thiamazol, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

The following drug interactions were reported for metronidazole, a chemically-related nitroimidazole and may therefore occur with tinidazole: Warfarin and other oral coumarin anticoagulants: Anticoagulant dosage may need adjustment during and up to 8 days after tinidazole therapy ( 7.1 ) (Fachinformation zu Tinidazol, Arzneimittelwechselwirkungen)

Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Tolmetin, Warnhinweise)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. (Fachinformation zu Triamcinolon, Arzneimittelwechselwirkungen)

The effect of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. (Fachinformation zu Triamteren und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (Fachinformation zu Valproat-Seminatrium (Divalproex), Arzneimittelwechselwirkungen)

The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. (Fachinformation zu Valproinsäure, Arzneimittelwechselwirkungen)

…other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine. (Fachinformation zu Valsartan, Arzneimittelwechselwirkungen)

…other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine. (Fachinformation zu Valsartan und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Arzneimittelwechselwirkungen)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (Fachinformation zu Vilazodon, Warnhinweise und Vorsichtsmaßnahmen)

Vitamin E kann die Thrombozytenaggregation und die Vitamin-K-abhängige Gerinnung hemmen, was das Blutungsrisiko unter Antikoagulanzien und Thrombozytenaggregationshemmern erhöht. (NIH Office of Dietary Supplements, Vitamin E)

Warfarin (CYP2C9 Inhibition) Other Oral Coumarin Anticoagulants (CYP2C9/3A4 Inhibition) Prothrombin Time Significantly Increased Not Studied In Vivo or In Vitro for other Oral Coumarin Anticoagulants, but Drug Plasma Exposure Likely to be Increased If patients receiving coumarin preparations are treated simultaneously with voriconazole, the prothrombin time or… (Fachinformation zu Voriconazol, Arzneimittelwechselwirkungen)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

Patients on oral warfarin anticoagulant therapy and zafirlukast should have their prothrombin times monitored closely and anticoagulant dose adjusted accordingly (see PRECAUTIONS, Drug Interactions ). (Fachinformation zu Zafirlukast, Warnhinweise)

Use with Warfarin: IMURAN may inhibit the anticoagulant effect of warfarin. (Fachinformation zu Azathioprin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Interaction studies with warfarin and acenocoumarol have failed to identify any clinically important effects of benazepril on the serum concentrations or clinical effects of these anticoagulants. (Fachinformation zu Benazepril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Anticoagulants: Direct Oral Anticoagulants (DOACs) rivaroxaban dabigatran edoxaban ↑ DOAC Refer to the DOAC prescribing information for concomitant administration with moderate CYP3A inhibitors and/or P-gp inhibitors. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Oral Anticoagulants Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects on blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide hydrochloride, a component of Librax. (Fachinformation zu Chlordiazepoxid und Clidiniumbromid, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Chlorpromazine diminishes the effect of oral anticoagulants. (Fachinformation zu Chlorpromazin, Vorsichtsmaßnahmen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Therapy consisting of prompt removal of the source of procoagulant material, replacement of depleted clotting factors and, in some cases, anti-coagulation with heparin should be instituted promptly. (Fachinformation zu Dinoproston, Warnhinweise und Vorsichtsmaßnahmen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (Fachinformation zu Dobutamin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

More patients experienced clinically significant INR elevations (≥5) usually within 1 week after starting dronedarone versus placebo in patients taking oral anticoagulants in ATHENA. (Fachinformation zu Dronedaron, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Omega-3-Präparate können die Blutungszeit leicht verlängern; die Kombination mit Antikoagulanzien wie Warfarin rechtfertigt eine Überwachung, obwohl klinisch bedeutsame Blutungen nicht durchgängig gezeigt wurden. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (Fachinformation zu Flecainid, Arzneimittelwechselwirkungen)

Anticoagulant: Warfarin Concentrations of warfarin may be affected. (Fachinformation zu Fosamprenavir, Arzneimittelwechselwirkungen)

In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed. (Fachinformation zu Fosinopril, Arzneimittelwechselwirkungen)

Interaction studies with warfarin have failed to identify any clinically important effects of fosinopril on the serum concentration or clinical effects of the anticoagulant. (Fachinformation zu Fosinopril und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin. (Fachinformation zu Imatinib, Arzneimittelwechselwirkungen)

Knoblauchpräparate können das Blutungsrisiko unter Antikoagulanzien wie Warfarin erhöhen. (NCCIH, Garlic)

Anticoagulants: Direct Oral Anticoagulants (DOACs) rivaroxaban dabigatran edoxaban ↑ DOAC Refer to the DOAC prescribing information for concomitant administration with moderate CYP3A inhibitors and/or P-gp inhibitors. (Fachinformation zu Lenacapavir, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Anticoagulants: warfarin, rivaroxaban ↑↓ warfarin ↑ rivaroxaban Concentrations of warfarin may be affected. (Fachinformation zu Lopinavir und Ritonavir, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Nevertheless, the effects of mefloquine on travelers receiving concomitant medications, particularly diabetics or patients using anticoagulants, should be checked before departure. (Fachinformation zu Mefloquin, Arzneimittelwechselwirkungen)

Arterial injection of heparin at the site of injury, followed by systemic anticoagulation. (Fachinformation zu Methohexital, Warnhinweise)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Fachinformation zu Mexiletin, Arzneimittelwechselwirkungen)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Fachinformation zu Milrinon, Arzneimittelwechselwirkungen)

Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. (Fachinformation zu Moexipril, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Phenothiazines can diminish the effect of oral anticoagulants. (Fachinformation zu Prochlorperazin, Vorsichtsmaßnahmen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

The anticoagulant effect of warfarin was not significantly changed by trandolapril. (Fachinformation zu Trandolapril, Arzneimittelwechselwirkungen)

Phenothiazines may diminish the effect of oral anticoagulants. (Fachinformation zu Trifluoperazin, Vorsichtsmaßnahmen)

Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction. (Fachinformation zu Acitretin, Arzneimittelwechselwirkungen)

Warfarin In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R- and S-warfarin. (Fachinformation zu Anastrozol, Arzneimittelwechselwirkungen)

Anticoagulants Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. (Fachinformation zu Bumetanid, Arzneimittelwechselwirkungen)

Warfarin A clinical study has shown that fesoterodine 8 mg once daily has no significant effect on the pharmacokinetics or the anticoagulant activity (PT/INR) of warfarin 25 mg. (Fachinformation zu Fesoterodin, Arzneimittelwechselwirkungen)